IL322310A - Methods for treating multiple sclerosis complex - Google Patents

Methods for treating multiple sclerosis complex

Info

Publication number
IL322310A
IL322310A IL322310A IL32231025A IL322310A IL 322310 A IL322310 A IL 322310A IL 322310 A IL322310 A IL 322310A IL 32231025 A IL32231025 A IL 32231025A IL 322310 A IL322310 A IL 322310A
Authority
IL
Israel
Prior art keywords
compound
formula
pharmaceutical composition
pharmaceutically acceptable
formulation
Prior art date
Application number
IL322310A
Other languages
English (en)
Hebrew (he)
Original Assignee
Noema Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Noema Pharma Ag filed Critical Noema Pharma Ag
Publication of IL322310A publication Critical patent/IL322310A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Preparation Of Fruits And Vegetables (AREA)
  • Medicinal Preparation (AREA)
IL322310A 2020-06-05 2021-06-04 Methods for treating multiple sclerosis complex IL322310A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063035313P 2020-06-05 2020-06-05
PCT/EP2021/065075 WO2021245281A1 (en) 2020-06-05 2021-06-04 Methods of treatment of tuberous sclerosis complex

Publications (1)

Publication Number Publication Date
IL322310A true IL322310A (en) 2025-09-01

Family

ID=76325558

Family Applications (2)

Application Number Title Priority Date Filing Date
IL322310A IL322310A (en) 2020-06-05 2021-06-04 Methods for treating multiple sclerosis complex
IL298709A IL298709A (en) 2020-06-05 2021-06-04 Methods for treating multiple sclerosis complex

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL298709A IL298709A (en) 2020-06-05 2021-06-04 Methods for treating multiple sclerosis complex

Country Status (13)

Country Link
US (3) US11684613B2 (enExample)
EP (1) EP4161512A1 (enExample)
JP (2) JP2023528895A (enExample)
KR (2) KR20230027145A (enExample)
CN (1) CN116056701A (enExample)
AU (1) AU2021285273A1 (enExample)
BR (1) BR112022024760A2 (enExample)
CA (1) CA3180794A1 (enExample)
CL (1) CL2022003435A1 (enExample)
IL (2) IL322310A (enExample)
MX (1) MX2022015407A (enExample)
PH (1) PH12023550016A1 (enExample)
WO (1) WO2021245281A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022015407A (es) * 2020-06-05 2023-05-16 Noema Pharma Ag Metodos de tratamiento del complejo de esclerosis tuberosa.
CN120641098A (zh) * 2023-02-02 2025-09-12 诺埃玛制药公司 Dravet综合征的治疗方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4508560A (en) 1981-11-11 1985-04-02 Ciba Geigy Corporation Certain pyridylacetylene compounds, compositions containing same and herbicidal methods of use
CN100548299C (zh) 2001-01-05 2009-10-14 伊莱利利公司 兴奋性氨基酸受体拮抗剂
TWI292318B (en) 2003-03-10 2008-01-11 Hoffmann La Roche Imidazol-4-yl-ethynyl-pyridine derivatives
UA80888C2 (en) * 2003-06-05 2007-11-12 Hoffmann La Roche Imidazole derivatives as glutmate receptor antagonists
HRP20080363T3 (hr) 2004-06-01 2008-09-30 F. Hoffmann - La Roche Ag Piridin-4-il-etinil-imidazoli i pirazoli kao antagonisti mglu5 receptora
EP1756086B1 (en) 2004-06-01 2008-06-04 F.Hoffmann-La Roche Ag Pyridin-4-yl-ethynyl-imidazoles and pyrazoles as mglu5 receptor antagonists
AU2007336369B2 (en) * 2006-12-21 2013-01-17 F. Hoffmann-La Roche Ag Polymorphs of a mGluR5 receptor antagonist
US8211882B2 (en) 2008-03-08 2012-07-03 Richard Delarey Wood Glutamate receptor modulators and therapeutic agents
JP2013505262A (ja) 2009-09-17 2013-02-14 バンダービルト ユニバーシティー ｍＧｌｕＲ５ネガティブアロステリックモジュレータとしての置換ヘテロアリールアミンカルボキサミド類似体、ならびに、その形成方法および使用方法
US20120039999A1 (en) 2010-08-11 2012-02-16 Ashish Chatterji Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists
US20120040008A1 (en) * 2010-08-11 2012-02-16 Ashish Chatterji Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists
CA2845578C (en) 2011-08-25 2016-02-16 Merck Sharp & Dohme Corp. Pyrimidine pde10 inhibitors
MX2022015407A (es) * 2020-06-05 2023-05-16 Noema Pharma Ag Metodos de tratamiento del complejo de esclerosis tuberosa.
TWI924682B (zh) 2020-07-30 2026-05-11 瑞士商諾埃瑪製藥公司 三叉神經痛之治療方法
US20240285637A1 (en) 2021-07-08 2024-08-29 The Royal Institution For The Advancement Of Learning/Mcgill University Phosphodiesterase inhibitors for the mitigation of fragile x syndrome symptoms
CN119677515A (zh) 2022-06-15 2025-03-21 美国政府健康及人类服务部 使用代谢型谷氨酸受体5拮抗剂或/和大麻素受体1拮抗剂治疗纤维化疾病
EP4584250A4 (en) 2022-09-06 2026-02-25 Biohaven Therapeutics Ltd POLYTHERAPIES INCLUDING METAL CHANNEL ACTIVATORS
US20260124188A1 (en) 2022-10-28 2026-05-07 Orphelion Ab mGluR receptor antagonists for use in prevention andor treatment of bone marrow lesions (BML) andor osteoporosis, cartilage loss, osteosclerosis and osteitis in a mammal
CN120641098A (zh) 2023-02-02 2025-09-12 诺埃玛制药公司 Dravet综合征的治疗方法
EP4680203A1 (en) 2023-03-14 2026-01-21 Prolevi Bio AB Compositions for sustained release of poorly soluble active ingredients

Also Published As

Publication number Publication date
CL2022003435A1 (es) 2023-10-20
US12702661B2 (en) 2026-08-11
PH12023550016A1 (en) 2024-03-11
KR20250116184A (ko) 2025-07-31
US20230100520A1 (en) 2023-03-30
US11998535B2 (en) 2024-06-04
IL298709A (en) 2023-02-01
JP2023528895A (ja) 2023-07-06
JP2025122066A (ja) 2025-08-20
BR112022024760A2 (pt) 2023-03-07
WO2021245281A1 (en) 2021-12-09
MX2022015407A (es) 2023-05-16
US20230277513A1 (en) 2023-09-07
EP4161512A1 (en) 2023-04-12
CN116056701A (zh) 2023-05-02
CA3180794A1 (en) 2021-12-09
AU2021285273A1 (en) 2023-01-19
KR20230027145A (ko) 2023-02-27
US20250099445A1 (en) 2025-03-27
US11684613B2 (en) 2023-06-27

Similar Documents

Publication Publication Date Title
IL290338B2 (en) Solid dispersions containing sgc activator
IL261249B2 (en) Dosage preparations containing Bruton's tyrosine kinase inhibitor
IL297642A (en) Methods for using t-type calcium channel modulators
US20250099445A1 (en) Methods of treatment of tuberous sclerosis complex
IL292005A (en) Solid-state crystalline forms of a selective potassium channel modulator
IL318638A (en) Taste-masking microspheres, preparation process therefor, and use thereof
IL312855A (en) ROCK2 inhibitor nanocrystalline preparation and method for its preparation
IL305576A (en) Objetive for the treatment of dementia
US20250345320A1 (en) Methods of treatment of trigeminal neuralgia
IL322318A (en) Methods for treating Dravet syndrome
IL273988B2 (en) Cannabidiol and chitosan compositions and methods of using the same
OA21484A (en) Methods of treatment of tuberous sclerosis complex.
IL293525A (en) Ganaxolone for use in the treatment of multiple sclerosis complex
CA3243616A1 (en) TREATMENT METHODS USING T-TYPE CALCIUM CHANNEL MODULATORS
IL292343A (en) Treatment of epileptic states with gabaa receptor modulators
OA21124A (en) Methods of treatment of trigeminal neuralgia.
IL295986A (en) Preparations that include methylphenidate drugs, production processes and their use
JP2026515884A (ja) 治療的使用のためのアンブロキソールの修飾形態
US20180153872A1 (en) Heteroaryl carbonitriles for the treatment of disease
IL303509A (en) A pharmaceutical preparation containing fexofenadine, famotidine and melatonin